Physician profile
Emma Clear
NPI 1790148955
$3,538.73
in general payments reported to CMS, 2019-2025
26 companies · $549 in 2025
The $549 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $288 · 2022: $1,320 · 2023: $668 · 2024: $714 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,846 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,846.13 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $407.76 | 2021-2025 | Veozah |
| Mayne Pharma Commercial LLC | $342.37 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $332.01 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $270.59 | 2022-2025 | Slynd |
| Myovant Sciences INC. | $226.90 | 2021-2022 | |
| Shield Therapeutics INC | $214.33 | 2022-2024 | Accrufer |
| Organon LLC | $176.90 | 2022-2025 | Nexplanon, Jada System |
| Abbvie INC. | $172.05 | 2022-2023 | Lo Loestrin Fe |
| Pfizer INC. | $143.78 | 2022-2024 | |
| Avion Pharmaceuticals | $142.66 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $136.77 | 2022 | |
| Therapeuticsmd, INC. | $129.62 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.05 | 2022-2025 | |
| Aspira Women'S Health INC | $112.89 | 2022 | |
| Merck Sharp & Dohme LLC | $103.42 | 2021-2025 | Gardasil 9, Gardasil |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $101.82 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Agile Therapeutics, INC. | $91.98 | 2022-2024 | Twirla |
| Medtronic, INC. | $67.70 | 2022-2023 | Truclear |
| Coopersurgical, INC. | $50.51 | 2022-2025 | Paragard T 380a |
| Exact Sciences Corporation | $49.72 | 2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $42.91 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Pacira Pharmaceuticals Incorporated | $37.45 | 2024 | Exparel |
| Becton, Dickinson and Company | $29.29 | 2022 | |
| Biogen, INC. | $19.48 | 2025 | Zurzuvae |
| Scynexis, INC. | $18.77 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Clear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.